Secnidazol`s effectiveness for the bacterial vaginosis treatment
Open Access
- 14 July 2023
- journal article
- research article
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 25 (2) , 202-206
Abstract
Background. Bacterial vaginosis is an infectious non-inflammatory syndrome with polymicrobial etiology associated with dysbiosis of the vaginal biotope. Aim. To assess the clinical efficacy and safety of Secnidox in treating bacterial vaginosis in women 2059 years. Materials and methods. The study included 30 patients (mean age 31.14.7 years) with bacterial vaginosis who received 2 g of secnidazole (Secnidox) as a single dose. All patients were followed up by an obstetrician-gynecologist at two visits. Results. Secnidazole provided sanitation of the vagina. Normalization of clinical symptoms and laboratory tests was reported. Conclusion. Secnidazole showed good therapeutic efficacy and normalization of the vaginal microflora.Keywords
This publication has 10 references indexed in Scilit:
- Secnidazol`s effectiveness for the bacterial vaginosis treatmentGYNECOLOGY, 2023
- Clinical and pharmacological rationale for principles of therapy for bacterial vaginosisVoprosy Ginekologii, Akušerstva i Perinatologii, 2021
- A Narrative Review of Current Challenges in the Diagnosis and Management of Bacterial VaginosisSexually Transmitted Diseases, 2020
- Vaginitis in Nonpregnant PatientsObstetrics & Gynecology, 2020
- Susceptibility of bacterial vaginosis (BV)-associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycinAnaerobe, 2017
- Secnidazole Treatment of Bacterial VaginosisObstetrics & Gynecology, 2017
- In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosisClinical Microbiology and Infection, 2010
- Vaginal microbial flora and outcome of pregnancyArchives of Gynecology and Obstetrics, 2009
- Rapid detection of Atopobium vaginae and association with organisms implicated in bacterial vaginosisMolecular and Cellular Probes, 2008
- In Vitro Activities of Garenoxacin (BMS 284756) against 108 Clinical Isolates of Gardnerella vaginalisAntimicrobial Agents and Chemotherapy, 2002